AFAna Fernández-Teijeiro

Ana Fernández-Teijeiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Fernández-Teijeiro has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Establishing a Multicenter Personalized Medicine Program in Childhood, Adolescent, and Young Adult Cancer in Spain: The SEHOP-PENCIL Project

    by Andrea Vilaplana, Asbleidy Carolina Torres, Adela Escudero López, Elisa Izquierdo, Sergio Manresa-Vera, Josep Escrivá-Fernández, Piedad Alba-Pavón, Lide Alaña, Angela Gutierrez-Camino, Carlos Rodríguez-Antolín, et al.

    Pediatric cancer care in Spain lacked a national personalized medicine program. The SEHOP-PENCIL initiative, established by the SEHOP, was designed to address this gap. A national survey identified the genomic sequencing needs of hospitals treating pediatric patients with cancer. Results showed improved access to targeted next-generation sequencing panels but revealed persistent variability in implementation, limited availability of advanced sequencing (whole-exome sequencing, whole-genome sequencing, RNA sequencing, and DNA methylation profiling), and gaps in cancer predisposition clinics and molecular tumor boards (MTBs). SEHOP-PENCIL is organized as a network of 10 specialized genomic centers serving 45 hospitals through a centralized inclusion system. The program standardizes patient eligibility, genomic workflows, and result interpretation, supported by a national MTB. This framework enables informed clinical decision making, ensures access to molecular diagnosis and innovative therapies, and supports systematic data collection to advance pediatric cancer research and personalized care. SEHOP-PENCIL represents a pioneering national model for integrating precision oncology into pediatric cancer care in Spain. By fostering collaboration, standardizing genomic practices, and promoting equitable access, it aims to reduce disparities and improve outcomes, offering a scalable example for other decentralized health care systems.

  • Open Access

    European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence

    by Alba Rubio-San-Simón, Timothy A. Ritzmann, Denise Obrecht-Sturm, Martin Benesch, Beate Timmermann, Pierre Leblond, John-Paul Kilday, Geraldina Poggi, Nicola Thorp, Maura Massimino, et al.


  • Reversible Cardiomyopathy Secondary to α-Interferon in an Infant

    by M.P. Angulo, A. Navajas, J.M. Galdeano, I. Astigarraga, A. Fernández-Teijeiro

    Interferon-α (IFN-α) is a biological response modifier with antiviral and tumoral effect that is used in the treatment of chronic myelogenous leukemias. Adverse effects are well documented and cardiovascular disturbances mostly include hypotension and tachycardia and rarely cardiomyopathy. We report on an infant with chronic myelomonocytic leukemia (CML) diagnosed at 3 months of age who was treated with increasing IFN-α dosage (2.5–5.5 million U/m2/day) given subcutaneously for 7.5 months. At that age, he presented anorexia, general malaise, and nocturnal sweating for about a week, followed by respiratory distress and tachycardia. Diagnosis of congestive heart failure was suspected and documented by cardiomegaly and echographic changes of left ventricular dilated cardiomyopathy, with a 40% left ventricular ejection fraction (EF) and 20% fractional shortening (FS). He was treated with digoxin, furosemide, and angiotensin converting inhibitors, and IFN-α was discontinued. Progressive improvement of cardiac function was observed within 7 months of the events with normalization of the echocardiographic findings (EF 60%, FS 31%). We should emphasize the possibility of severe and reversible cardiac toxicity of IFN-α in infancy.